Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by FredTheVoiceon Jul 19, 2019 12:01pm
132 Views
Post# 29940101

RE:2020

RE:2020 Im staying in. Because Im a beleiver that things turn around rapidly with biothech when the foundations are good, and milestones are interesting.

Good luck to you to. You made a big point by pointing out 2020.......that is the major problem right now with TH/THERF...........everything will be great in a year or two.......but what ABOUT NOW ? And with FDA (NASH), sales of Trogarzo, and Egrifta, a lot need some NOW's...........

And, I must say, like you, the market is saying right now: "Not impressive !".

The choice to stay, means you beleive in the GAME CHANGERS coming soon (publication of Grinspoon, good sales for Trogarzo, Europe approval, and possibly an extension of the label for EGRIFTA before the end of year.......that would be a MAJOR gam changer......).

Im in. I understand that some are out ! Good luck.

FTV. 
Bullboard Posts